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Abstract
Rationale: Despite preclinical success in regenerating and revascularizing the infarcted heart using angiogenic growth
factors or bone marrow (BM) cells, recent clinical trials have revealed less benefit from these therapies than expected.
Objective: We explored the therapeutic potential of myocardial gene therapy of placental growth factor (PlGF), a VEGF-
related angiogenic growth factor, with progenitor-mobilizing activity.
Methods and Results: Myocardial PlGF gene therapy improves cardiac performance after myocardial infarction, by inducing
cardiac repair and reparative myoangiogenesis, via upregulation of paracrine anti-apoptotic and angiogenic factors. In
addition, PlGF therapy stimulated Sca-1
+/Lin
2 (SL) BM progenitor proliferation, enhanced their mobilization into peripheral
blood, and promoted their recruitment into the peri-infarct borders. Moreover, PlGF enhanced endothelial progenitor
colony formation of BM-derived SL cells, and induced a phenotypic switch of BM-SL cells, recruited in the infarct, to the
endothelial, smooth muscle and cardiomyocyte lineage.
Conclusions: Such pleiotropic effects of PlGF on cardiac repair and regeneration offer novel opportunities in the treatment
of ischemic heart disease.
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Introduction
Human placental growth factor (PlGF) was originally discovered
by Persico et al in 1991 as an angiogenic factor [1]. Loss or
inhibition of PlGF does not affect normal health, but impairs
angiogenesis in pathological conditions [2,3]. Because PlGF has a
higher disease-specific activity than VEGF and other cytokines,
and does not affect quiescent vessels in healthy tissues, it is an
attractive therapeutic target. An increasing number of reports has
now documented the role of PlGF in the angiogenic switch in
numerous malignant, inflammatory and ischemic disorders [3–6].
Interestingly, cardiac PlGF expression levels predict the improve-
ment of left ventricular function in patients with acute MI [7].
Apart from activating downstream signaling through its own
receptor VEGFR-1 (also termed Flt-1), PlGF also transactivates
VEGFR-2 (also termed Flk-1) via an intermolecular crosstalk
between Flt-1 and Flk-1 [8]. Although PlGF and VEGF activate a
similar signaling pathway, the bioactivity of PlGF for angiogenesis
is not completely the same as that of VEGF. A recent investigation
revealed that anti-PlGF therapy inhibits the growth of VEGFR-
inhibitor resistant tumors without affecting healthy vessels [9].
This important finding indicates that PlGF might also have unique
potency that is distinct from VEGF in not only tumor angiogenesis
but also ischemic neovascularization. Besides affecting endothelial
cells (ECs) and smooth muscle cells (SMCs), PlGF is also a potent
BM progenitor-active cytokine. Transplantation of BM from wild-
type donors into PlGF knockout recipients rescues the angiogenic
defects [2], while PlGF promotes the mobilization of marrow-
derived hematopoietic and endothelial progenitors [10,11].
Infusion of PlGF protein or adenoviral PlGF gene transfer
enlarges collateral branches and angiogenesis in skin and ischemic
limbs in preclinical animal models [3,12]. Systemic delivery of
recombinant PlGF also stimulates neovascularization in the infarct
scar in mice when given during a one week period after MI.
3 A
recent study revealed that intramyocardial administration of
PlGF1 protein increases endothelial cell density in the rat infarcted
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LV global function [13]. However, the effect of PlGF on LV
infarct size and cardiac regeneration via the recruitment of BM
progenitors has not been studied previously. In addition, the
therapeutic consequences of PlGF delivery on long-term cardiac
performance after the arrest of PlGF administration remain
unknown. This is relevant, as various angiogenic factors induce
only a transient angiogenic response as long as they are being
administered, and the newly formed vessels often regress once
angiogenic therapy is arrested [14]. Since injection of naked DNA
is generally considered to be safer than viral gene transfer, we
assessed the therapeutic potential of local intramyocardial delivery
of a PlGF expression DNA vector.
Our findings indicate that PlGF improved cardiac performance
after acute MI by inducing not only local angiogenesis, but also
vasculogenesis and cardiomyogenesis via recruitment of BM-
derived progenitors to the infarcted myocardium. The present
data offer novel therapeutic opportunities for PlGF gene therapy
in patients with ischemic heart disease.
Materials and Methods
Experimental animals
Male Sprague-Dawley Rats (Charles River Laboratories,
Tokyo, Japan) aged 6 to 7 weeks and weighing 160,185 g were
used for functional assessment of the present study. Male C57BL/
6 mice (Charles River Laboratories) aged 7 to 9 weeks were used
for proliferation and migration assay in BM cells. GFP transgenic
mice (GFP-Tg mice; C57BL/6TgN [act EGFP] Osb Y01) were
used in the bone marrow transplantation (BMT) study as donor
mice, whereas female athymic nude rats (F344/N Jcl rnu/rnu)
(CLEA Japan, Tokyo, Japan) aged 4 weeks and weighing 58,70 g
were used for the BMT study as recipients. All experimental
procedures were conducted in accordance with the Japanese
Physiological Society Guidelines for the Care and Use of
Laboratory Animals and the study protocol was approved by the
Ethics Committee in RIKEN Center for Developmental Biology
(H17-483). All imaging experiments of infarcted rat hearts were
performed in conformance with the SPring-8 Guideline for Care
and Use of Laboratory Animals in synchrotron radiation
microangiography (SRM) examination (BL28B2).
Construction of human PlGF plasmid and transfection in
vitro
TA cloning was performed according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA) [15]. The specific primer
for 59-based on the sequence of human placental growth factor 1
(PlGF 1) cDNA was 59-TTA AAG CTT CCC TCG GGA CGT-
39 and 59-TAA ATA CTC GAG CCG GGT GCG-39. PCR
products were ligated into PCR-II TOPO vector (Invitrogen).
PlGF cDNA was released as Hind III and XhoI fragment and
subcloned into pcDNA3 plasmid (Invitrogen). Then, ires EGFP
(ires: internal ribosomal entry site) was subcloned between the XhoI
and XbaI sites. In brief, the expression vector pcDNA3 consisted of
a 5.4 Kb plasmid that includes the human PlGF1 coding gene,
transcriptionally regulated by the cytomegalovirus promoter/
enhancer, referred to as plasmid of human PlGF1 (pPlGF1). An
SV40 terminator is located 39 to the PlGF1 coding gene or ires-
EGFP. Preparation, purification and quality control analyses of
the plasmid from transformed E. coli cultures were performed
under GMP conditions. The purified plasmid was stored in vials at
280uC. A total of 100, 500 or 1,000 mg of DNA in 5 aliquots of
150 ml of sterile saline was prepared for in vivo study. To confirm
the expression and secretion of PlGF protein following pPlGF1
transfer in vitro, RT-PCR and western blotting using transfected
H9C2 cells (rat cardiomyoblast cell line) 2 days after transfection
was performed according to the manufacturer’s instructions
(Roche, Penzberg, Germany). Plasmid encoding IRESeGFP and
empty vector (pcDNA3) were also used as a negative control. In
brief, these plasmids were transiently transfected into H9C2 cells
(1610
5 cell/well) using FUGENE 6 transfection reagent (Roche),
and cells were allowed to recover for 24 hours in Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco BRL, Grand Island,
NY) containing 10% fetal bovine serum (FBS) (Hyclone Labora-
tories, Logan, UT). The following day, cells were washed and
incubated for 48 hours in DMEM with 10% FBS.
Induction of myocardial infarction and gene transfer
Six-week-old male Sprague-Dawley Rats were anesthetized with
ketamine and xylazine (60 mg/kg and 10 mg/kg, respectively, IP).
Myocardial infarction (MI) was induced by ligating LAD as
described previously. The proximal left coronary artery under the
tip of the left atrial appendage is ligated using a 6-0 prolene suture.
Septal branches are not ligated. Proximal LAD ligation in a rat
model creates a reproducibly large lateral wall infarction. Twenty
minutes after MI, rats received intramyocardial gene transfer of
500 mg empty vector (Mock) or 500 mg pPlGF1 resuspended with
80 ml of PBS or the same volume of PBS without plasmid (n=8 in
each group). After gene transfer was completed, the thorax was
closed.
Echocardiography and hemodynamic measurements
Transthoracic echocardiography (SONOS 5500, Philips Med-
ical Systems) was performed to evaluate LV function immediately
before and 5 and 28 days after MI, as described previously. Under
general anesthesia with ketamine and xylazine, LV end-diastolic
diameter (LVEDD), LV end-systolic diameter (LVESD) and
fractional shortening (FS) were measured at the midpapillary
muscle level. Regional wall motion score (RWMS) was evaluated
per published criteria. Immediately after the final echocardiogra-
phy on day 28, the rats underwent cardiac catheterization for
more invasive and precise assessment of global LV function as
described previously. A 2.0 Fr micromanometer-tipped conduc-
tance catheter (SPR 838, Millar Instruments Inc., Houston, TX)
was inserted via the right carotid artery into the LV cavity. LV
pressure and its derivative (dP/dt) were continuously monitored
using a multi-channel recording system (Pressure-Volume Con-
ductance System ARIA and Pressure-Volume Analysis Using P-V
Analysis Software [Millar Instruments Inc.] and PowerLabH DAQ
System [ADInstruments, Australia]). HR, EF, +dP/dt and 2dP/
dt were continuously recorded for 20 minutes. All data were
acquired under stable hemodynamic conditions. All procedures
and analyses were performed by an experienced researcher who
was blinded to the treatment. The authors randomly assigned the
animals to each treatment group.
Tissue harvesting
All rats were killed 4, 7 and 28 days after gene transfer with an
overdose of ketamine and xylazine. At necropsy, hearts were sliced
in a broad-leaf fashion into 4 transverse sections from apex to base,
embedded in OCT compound, snap-frozen in liquid nitrogen, and
stored at 280uC for Masson-trichrome staining and immunohis-
tochemistry. Rat hearts in OCT blocks were sectioned, and 5 mm
serial sections were collected on slides, followed by fixation with
4.0% paraformaldehyde at 4uC for 5 minutes and stained
immediately. Total RNA for RT-PCR and real-time PCR, and
protein for western blotting was isolated by selective dissection of
the fibrosis, peri-infarct and remote areas in the LV myocardium.
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Histochemical staining with isolectin B4 (Vector Laboratories,
Burlingame, CA) was performed, and capillaries were recognized
as tubular structures positive for isolectin B4. Histological capillary
density was evaluated by morphometric examination of 5
randomly selected fields of tissue sections recovered from segments
of LV myocardium subserved by the occluded LAD. To elucidate
the severity of myocardial fibrosis, Masson-trichrome staining was
performed on frozen sections from each tissue block, and the
stained sections were used to measure the average ratio of fibrosis
area to the entire LV area (% fibrosis area). All morphometric
studies were performed by 2 examiners who were blinded to
treatment.
RT-PCR analysis of ischemic heart tissue
Total RNA was obtained from tissues of rat heart (fibrosis, peri-
infarct and remote areas) at days 3, 7 and 14 using Tri-zol (Life
Technologies, Grand Island, NY) according to the manufacturer’s
instructions. In brief, the first-strand cDNA was synthesized using
the RNA LA PCR Kit Ver1.1 (Takara, Otsu, Japan), amplified by
Taq DNA polymerase (Advantage–GC cDNA PCR Kit (Clon-
tech, Mountain View, CA) and AmpliTaq Gold DNA polymerase
(Applied Biosystems, Foster City, CA)). PCR was performed using
a PCR thermalcycler (MJ Research PTC-225, Bio-Rad Labora-
tories, Waltham, MA). The total (human and rat) b-actin was
amplified by Taq DNA polymerase (AmpliTaq Gold DNA
polymerase, Applied Biosystems) using the following conditions:
35 cycles of 30 seconds initial denaturation at 94uC, annealing at
56uC for 1 minute, and 30 seconds of extension at 72uC according
to the manufacturer’s instructions. Human PlGF (hPlGF) was
amplified by Taq DNA polymerase (Advantage–GC cDNA PCR
Kit) under the following conditions: 37 cycles of 30 seconds initial
denaturation at 94uC, annealing at 68uC for 3 minute, and
7 minutes of elongation at 64uC according to manufacturer’s
instructions. Subsequently, PCR products were visualized in 1.5%
ethidium bromide-stained agarose gels. Human heart RNA
distributed from Clontech (premium RNA) was used as positive
control. Primers: To avoid interspecies cross-reactivity of the
primer pairs between human and rat genes, we designed the
following human-specific primers using Oligo software (Takara).
None of the primer pairs showed cross-reactivity to rat genes (data
not shown). PlGF primer sequence (224 bp): sense TTA GGA
GCA GCA TGG TGA CAT TGG C; antisense CGG CTC GTC
AGA GGT GGA AGT GGT A; b-actin primer sequence
(427 bp): sense ACC CTA AGG CCA ACC GTG AAA; antisense
TCA TTG CCG ATA GTG ATG ACC TGA C.
Real-time PCR analysis of gene expression
Real-time PCR was performed on an ABI PRISM 7000
sequence detector (Applied Biosystems) as described previously.
Total RNA was prepared as described above. The expression of
related genes was quantified using the SYBR green reagent (26
SYBR Green Supermix; Bio-Rad, Hercules, CA) following the
manufacturer’s instructions on a Bio-Rad Cycler. Multiple PCR
was performed under optimized conditions: 95uC denatured for
3 minutes, followed by 40 cycles of 45 seconds at 94uC,
45 seconds at 55uC, and 45 seconds at 72uC using the primers
as described below. Primer for human-specific PlGF was
confirmed not to cross-react with rat genes by using rat heart
samples. Similarly, specificity of mouse-specific primers was
demonstrated using rat tissue samples (data not shown).
Primers: hPlGF, forward, 5–TGG AGC ACA TGT TCA GCC
C-3, reverse, 5-GCT GCA TGG TGA CAT TGG C-3; rPlGF,
forward, 5-GTT GGC TGT GCA CTC CCA G-3, reverse, 5–
GTT GGC TGT GCA CTC CCA G-3; rFlt-1, forward, 5–TGT
CGG CTG CAG TGT GTA AGT-3, reverse, 5–CCC AAT TGC
TGG ATA TCT GGA; rVEGF, forward, 5–GAC AGA AGG
GGA GCA GAA AG-3, reverse, 5–AAG CAA TGC TGT TGT
CAC CTT CCC-3; rSDF-1, forward, 5–CGT GGG CTC TGA
GTT TTC GA-3, reverse, 5–GAT TGA AAC CCA GAA TCC
CC-3;rAng-1,forward,5 –CGA ATTCAACATGGGCAATG-
3, reverse, 5 –TCG CAC TCT CAC GGC AGT T-3; rAng-2,
forward, 5 –CTA CAG GAT TCA CCT TAC AGG ACT CA-3,
reverse, 5 –CTT CCT GGT TGG CTG ATG CT-3; rIGF-1,
forward, 5 –GTC CGC TGC AAG CCT ACA AA-3, reverse, 5 –
TGA GTC TTG GGC ATG TCA GTC T-3; rIGFR, forward, 5 –
CAC ACC GGA CGA CAA CAC A, reverse, 5 – CAC GCA CAC
GCC TTT GTA GT -3; mFlt-1, forward, 5–TCG GCC ATC
ATC TGA ATG TG-3, reverse, 5 –TCC ACG ATC ACC ATG
AGA-3; mFlk-1, forward, 5–GAG CTC TCC GTG GAT CTG
AA-3, reverse, 5–AAC AAG CCT GAG CTG GC-3; mCXCR4,
forward, 5–GAA TGA GCG TCT AGG CAG GA-3, reverse, 5–
CAG CTG AGG ATC ACG GCT-3; and b-actin, forward, 5 –
AAG TCC CTC ACC CTC CCA AAA G-3, reverse, 5 –AAG
CAA TGC TGT CAC CTT CCC- 3. No other products were
amplified because melting curves showed only one peak in each
primer pair. Fluorescence signals were measured over 40 PCR
cycles.Thecycle numberatwhichthesignals crossed a threshold set
within the logarithmic phase was recorded. For quantitation, we
evaluated the difference in cycle threshold between the AP-treated
group and vehicle control of each gene. The efficiency of
amplification of each pair of primers was determined by serial
dilutions of templates and all were 0.9. Each sample was normalized
with the loading reference b-actin. The Ct values used were the
means of triplicate replicates. Experiments were repeated at least
three times.
ELISA assay
Total hPlGF and rVEGF protein concentrations were deter-
mined by a solid-state ELISA system with Quantikine PlGF and
VEGF ELISA kit (R&D Systems) according to the manufacturer’s
instructions. Each plasma sample was tested in triplicate.
TUNEL assay
We obtained rat heart samples 4 days after gene transfer.
Frozen heart specimens were sectioned as described above.
Apoptosis was detected by the TUNEL assay (Roche) according
to the manufacturer’s instruction. Immunohistochemistry with
cTn-I was performed to identify mature cardiomyocytes (CMCs)
in rat hearts. The number of apoptotic CMCs was evaluated by
counting the number of double-positive cells for TUNEL and
cTn-I in 5 randomly selected fields within the rat ischemic
myocardium at day 4. The % apoptotic CMCs was calculated as
the ratio of the number of apoptotic CMCs to the total number of
CMCs. The morphometric examination was performed by two
investigators blinded to the treatment group.
Western blotting
Western blot analysis was performed as described previously.
Heart tissue and BM- Sca-1
+/Lin
2 (SL) cell extracts were
subjected to SDS-PAGE, transferred to PVDF membranes and,
following antibody incubations, developed with enhanced chemi-
luminiscence detection kit. Loading controls were performed with
the following antibodies. In brief, LV specimens (muscle) obtained
for Western blotting were snap-frozen in liquid nitrogen without
Pleiotropic Effects of PlGF on Cardiac Repair
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needle after homogenization in 10 volumes of T-PERH lysis buffer
(Tissue Protein Extraction Reagent) (PIERCE, Rockfold, IL) with
protease inhibitor (Roche). After normalizing for protein content,
50 mg of each sample was electrophoresed on a 12.0% SDS-
polyacrylamide gel following 5 minutes of denaturation at 95uC. A
wet transfer apparatus was used to transfer proteins to PVDF
membranes, which were then blocked with 5% nonfat dry milk
and FBS in PBS containing 0.05% Tween 20. Immunoblotting
was performed using the monoclonal antibody against PlGF (1:500
dilution) and polyclonal antibodies against a-tubulin (1:3000) (both
from Abcam, Cambridge, UK), Bcl-xL (1:500) (Southern Biotech,
Birmingham, AL) and Akt (1:1000) (Cell Signaling Beverly, MA).
The secondary antibodies for immunoblotting are as follows: anti-
rabbit IgG HRP for PlGF, a-tubulin and Akt, and anti-mouse IgG
HRP for Bcl-XL (both from Amersham Bioscience, Buckingham-
shire, UK). PI3K-Akt pathway was detected by western blotting
using PathScan Multiplex Western Mixture I (Cell Signaling)
according to the manufacturer’s instructions.
Growth factors
Recombinant human growth factors and cytokines, i.e. stem cell
factor (rh-SCF) and thrombopoietin (rh-TPO) were kindly
donated by Kirin Brewery Co (Tokyo, Japan). rh-Flt-3 ligand
and insulin-like growth factor-1 (rh-IGF-1) were purchased from
Peprotec and heparin from Shimizu Pharmaceutical Co, Ltd.,
(Tokyo, Japan).
Isolation of SL cells
BM-MNCs were isolated from the BM of C56BL/6 mice or
xeno-rats. The Sca-1
+ and lineage
2 (Sca-1
+/lin
2) fraction of the
BM- mononuclear cell (MNC) population was sorted by
fluorescence-activated cell sorting (FACSAria
TM) (Becton Dick-
inson Immunocytometry Systems, Mountain View, CA). Prior to
the sorting procedure, BM-MNCs were stained with a cocktail of
biotinylated monoclonal antibodies against various lineage mark-
ers, including B220/CD45R (clone RA3-6B2); CD11b/Mac-1
(clone Mi/70); Gr-1 (clone RB6-8C5); Thy1.2 (clone 53-2.1);
CD3e (clone 145-2C11); CD4 (clone RB6-8C5); CD8 (clone 53-
6.72); and TER 119 (clone Ly-76; all from BD Pharmingen, San
Diego, CA) for 20 minutes at 4uC. The cells were stained with a
PE-conjugated anti-Sca-1 antibody (BD Pharmingen) and APC-
conjugated streptavidin (BD pharmingen) for 20 minutes at 4uC.
Expansion culture of isolated SL cells (proliferation assay)
Isolated 1.5610
3 BM-SL cells were cultured in each well of a
96-well tissue culture dish (Primaria
TM, BD Falcon, MA) using
serum free culture media (STEM SPAN
TM, Stem Cell Tec,
Tokyo, Japan) containing 100 ng/ml hSCF, 100 ng/ml hFlt-3
ligand, 20 ng/ml hTPO in the presence or absence of 50 ng/ml
PlGF for 7 days. To assess the effect of PlGF on the proliferation
activity of SL cells, the total number of expanded SL cells in each
well was counted in a blinded manner under 6200 magnification.
BrdU incorporation
Cell proliferation was also evaluated by measuring the
incorporation of BrdU, indicating the S phase of the cell cycle.
BrdU incorporation was detected by using kits purchased from
Roche according to the manufacturer’s instructions. For immu-
nofluorescent assay, cells were cultured in the presence or absence
of PlGF (0, 0.1, 1 or 50 ng/ml) for 4 days. BrdU was added to the
cells and reincubated for 4 hours. After removing the culture
medium, the cells were fixed and DNA was denatured in one step
by adding FixDenat. Thereafter, the anti-BrdU-POD, which binds
to the incorporated BrdU in newly synthesized cellular DNA, was
added for 90 minutes. Further development was accomplished
with substrate solution for 3 minutes. Light absorbance at 490 nm
in each plate was quantified by ELISA plate reader (Bionetics
Laboratory) [8]. The absorbance value for each concentration of
PlGF was corrected by subtracting the value of the blank (without
BrdU loading).
Migration assay
To investigate PB-SL cell migration activity, a modified Boyden
chamber assay was performed using a 48-well microchemotaxis
chamber (NeuroProbe). PlGF was diluted to the appropriate
concentration in DMEM, supplemented with 0.1% BSA, and
30 ml of the final dilution was placed in the lower compartment of
a Boyden chamber (PlGF concentration: 1, 20 or 100 ng/ml).
Isolated PB-SL cells (1610
4 cells) were suspended in 50 mlo f
DMEM supplemented with 0.1% BSA, and antibiotics for 6 hours
at 37uC. The filter was then removed, and the cells on the filter
were counted manually in random high-power fields (6100) in
each well. All groups were studied at least in triplicate.
Experimental animals in BMT
To evaluate the effect of pPlGF1 on BM-derived stem/
progenitor cells, we established BMT from GFP transgenic mice
to nude rats (xeno-rats). Low-density BM-MNCs of GFP
transgenic mice were isolated by density-gradient centrifugation
with Histopaque-1083 (Sigma). The immunodeficient rats were
lethally irradiated with 8.0 Gy and the 2610
7 donor BM-MNCs
suspended in 100 ml of PBS were injected intravenously from the
tail vein of immunodeficient rats. Four weeks post-BMT, by which
time the BM of the recipient rat was reconstituted by donor mice’s
cells, these xeno-rats underwent induction of MI, and were
randomly assigned to treatment with PlGF plasmid, Mock or PBS.
The rats were killed 1, 7 and 28 days after treatment.
EPC colony forming assay (EPC-CFA)
To further investigate the effect of pPlGF1 transfer on the
vasculogenic potential of BM-SL cells isolated from xeno-rats, we
performed the endothelial progenitor cell (EPC)-CFA using the
cells obtained 7 days after the gene therapy, as described below.
Isolated SL cells were seeded into each semi-solid culture system.
Semi-solid culture medium for EPC-CFA was adjusted using
serum free 1.0% methylcellulose in Iscove Modified Dalbecco’s
Medium (IMDM) (MethoCult
TM SF
BIT H4236, Stem Cell Tech.),
containing 30% FBS (JRH Bioscience), 50 ng/ml rh-VEGF,
50 ng/ml rh-bFGF, 100 ng/ml rh-SCF, 50 ng/ml rh-IGF-1,
20 ng/ml rh-IL3, 50 ng/ml rh-EGF, and 2 IU/ml heparin.
Isolated SL cells (500 cells per dish) were seeded into a 35 mm
hydrophilic tissue culture dish (Primaria
TM, BD Falcon) to
promote cell adhesion.
In an EPC-CFA, two types of cell clusters, i.e. non-adherent or
poorly-adherent cells exhibiting large (20 to 50 mm) and small (10
to 20 mm) cell diameters, respectively usually appear 8 to 12 days
after initiation of the assay. At day 10 to 14, the large cells start to
adhere to the tissue culture dish and acquire a more spindle-like
shape. The small cells gradually start to proliferate without,
however, adhering or changing their shape. After 14 to 18 days,
these two types of cells were independently recognized as definite
colony forming units (CFUs). The CFUs containing large cells
(large EPC colony) tightly adhered as sheets of spindle-like cells (50
to 200 mm). In contrast, CFUs containing small cells (small EPC
colony) were weakly adherent small round cells. We previously
reported that both EPC colonies show acetyl-LDL uptake and are
Pleiotropic Effects of PlGF on Cardiac Repair
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colonies also express CD31, VEGFR-2 and VE-cadherin. EPCs in
small colonies are more immature and capable of differentiating
into more mature EPCs in large EPC colonies, as observed with
time-lapse microscopic examination. Eighteen to twenty-one days
later, the methylcellulose was resolved and gently removed with a
pippetor after adding 1 ml of ice-cold PBS. Then, immediately
after adding 1 ml of 5% FCS-EBM-2 medium with endothelial
growth supplement kit (EGM-2 MV single quots, Clonetics)
without hydrocortisone, two types of adherent colonies, small EPC
colony and large EPC colony, were counted under light
microscopy.
Immunofluorescent staining
To detect incorporation of BM-derived SL cells in ischemic
myocardium of xeno-rats, double immunohistochemistry was
performed with the following antibodies: GFP (Molecular Probes,
Carlsbad, CA) and Sca-1 (BD Pharmingen, San Diego, CA).
Double staining for GATA4 or MEF2C (Santa Cruz, CA) and
GFP or Sca-1 was performed to detect BM-derived cells
expressing early cardiomyogenic transcription factor in ischemic
myocardium of xeno-rats at day 7. Double staining for GATA6 or
Ets-1 (Santa Cruz, CA) and GFP or Sca-1was performed to detect
BM-derived cells expressing early vasculogenic transcription factor
in the ischemic myocardium of xeno-rats at day 7. Moreover,
double staining for cTn-I (Chemicon International) as mature
CMC marker and GFP was performed to detect cardiomyogenic
plasticity of incorporated BM-derived GFP+ cells at day 28.
Double immunohistochemistry with GFP and SMA was per-
formed to detect double-positive cells as BM-derived smooth
muscle cells (SMCs) in rat myocardium. Similarly, double
immunohistochemistry with isolectin B4 (Vector Laboratories)
and GFP was performed to detect double positive cells as BM-
derived endothelial cells (ECs) in ischemic myocardium. Immu-
nohistochemistry for SDF-1 (R&D System) was performed to
assess the underlying mechanism of enhancement of the
recruitment of BM-derived progenitor cells after pPlGF1 gene
transfer. The secondary antibodies for each immunostaining were
as follows: Alexa Fluor 488 or 594-conjugated goat anti-mouse
IgG2a and goat anti-rabbit IgG (Molecular Probes, Carlsbad, CA)
for GFP staining, Alexa Fluor 594-conjugated goat anti-mouse
IgG1 (Molecular Probes) for Sca-1 and SDF-1 staining, Alexa
Fluor 488 or 594-conjugated goat anti-rabbit IgG (H+L)
(Molecular Probes) for GATA4, GATA6 or Ets-1 staining, Alexa
Fluor 488 or 594-conjugated mouse anti-goat IgG (Molecular
Probes) for MEF2C staining, Alexa Fluor 488-conjugated goat
anti-mouse IgG2a (Molecular Probes) for cTn-I staining and Alexa
Fluor 488-conjugated goat anti-mouse IgG2a (Molecular Probes)
for SMA. DAPI solution was applied for 5 minutes for nuclear
staining.
To detect the growing endothelial cells or cardiomyocytes,
sections were immunostained with anti-phospho-Akt (Ser473)
rabbit monoclonal antibody (Cell Signaling Technology Inc.,
Danvers, MA) or anti-ACTIVEH MAPK rabbit polyclonal
antibody (pTEpY) (Promega, Madison, WI) and Alexa Fluor
594-conjugated isolectin B4 (Invitrogen, Frederick, MD) or mouse
anti-cardiac troponin I antibody (Millipore, Billerica, MA)
according to the manufacturer’s instructions, followed by the
incubation with the secondary antibody Alexa Fluor 488-
conjugated donkey anti-rabbit IgG or Alexa Fluor 594-conjugated
donkey anti-mouse IgG2b (Invitrogen). The sections were
counterstained with DAPI. Images were captured with a BX51
light microscope (Olympus, Tokyo, Japan).
To detect the integration of the BM-derived cells with host
cardiomyocytes in ischemic myocardium of xeno-rats, immuno-
histochemistry was performed. Frozen sections were fixed in 4%
PFA/PBS for 10 minutes at 4uC and blocked with 5% normal
goat serum/0.1% TritonX-100 in PBS. Sections were immuno-
stained with anti-green fluorescent protein (GFP) rabbit polyclonal
antibody (Thermo Fisher Scientific, Waltham, MA) and purified
mouse anti-connexin-43 mouse monoclonal antibody (Pharmin-
gen, San Diego, CA), followed by the secondary antibodies Alexa
Fluor 488-conjugated goat anti-rabbit IgG antibody and Alexa
Fluor 594-conjugated goat anti-mouse IgG1 antibody (Invitrogen,
Frederick, MD). Sections were additionally stained with mouse
anti-cardiac troponin I antibody (Millipore, Billerica, MA),
followed by aminomethylcoumarin-conjugated goat anti-mouse
IgG(H+L) antibody (Jackson ImunoResearch Laboratories, West
Grove, PA).
Culture of sorted BM Sca-1
+/Lin
2 cells for
cardiomyogenic and vasculogenic differentiation and
quantitative RT-PCR
BM cells were obtained by flushing the tibias and femurs of
C57BL/6 mice. The Sca-1
+/Lin
2 fraction of the BM cells was
sorted by fluorescence-activated cell sorting (FACSAria
TM) (BD
Biosciences, San Jose, CA). Prior to the sorting procedure, Lin
2
cells were immunomagnetically isolated by depleting mature
hematopoietic cells such as T cells, B cells, monocytes/macro-
phages, granulocytes and erythrocytes using the biotinylated
mouse lineage depletion cocktail (IMag, BD Pharmingen, San
Jose, CA), containing CD3e, CD11b/Mac-1, CD45R/B220, Gr-1
and TER119. The cells were then stained with phycoerythrin
(PE)-conjugated anti-Sca-1 antibody (BD Pharmingen), biotiny-
lated mouse lineage depletion cocktail and streptavidin-APC/Cy7
(BioLegend, San Diego, CA) for 20 minutes at 4uC.
Sorted BM SL cells were plated into a 48-well plate coated with
rat vitronectin (Sigma-Aldrich, St.Louis, MO) at a density of
5610
5 cells/well and cultured with 2%FBS/EBM-2 supplemented
with 10 nM dexamethasone (Sigma-Aldrich), 0, 1, 10 or 100 ng/
mL recombinant human PlGF (R&D Systems, Minneapolis, MN),
and with or without 1 ng/mL mouse VEGF (PeproTech, Rocky
Hill, NJ) for 7 days. Total RNA was then obtained using RNeasy
Mini kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions.
The first-strand cDNA was synthesized using the PrimeScript
RT reagent Kit (Takara Bio, Otsu, Japan) and real-time
quantitative RT-PCR was performed with ABI Prism 7700
(Applied Biosystems, Foster City, CA) using SYBR Green Master
Mix Reagent (Applied Biosystems).
The sequences of primers were as follows:
GATA4
Fw: TCCAGTGCTGTCTGCTCTGAA
Rv: TGGCCTGCGATGTCTGAGT
cTnI
Fw: AGATCTCCGCCTCCAGAAAAC
Rv: TCCATCTCCTGCTTCGCAAT
Flt-1
Fw: TCGGCCATCATCTGAATGTG
Rv: TCCACGATCACCATCAGAGG
VE-cad
Fw: TCGGGAGCATGCCAAGTT
Rv: TGGGCACCCCGTTGTC
eNOS
Fw: CCGAAGCAGCACTCTTGCA
Rv: CCGCAATGAGCCCTTTCTT
GAPDH
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Rv: ACCACCTTCTTGATGTCATCATACTT
Statistical analysis
The results were statistically analyzed using a software package
(Statview 5.0, Abacus Concepts Inc., Berkeley, CA). All values
were expressed as mean6standard error (mean6SE). Compari-
sons among more than 3 groups were made using one-way analysis
of variances (ANOVAs). Post-hoc analysis was performed using
Scheffe’s PLSD test. Differences of P,0.05 were considered to
denote statistical significance.
Results
pPlGF1 upregulates angiogenic factors in ischemic
myocardium
Using real-time RT-PCR, we also examined whether pPlGF1
gene transfer altered the endogenous myocardial expression of the
angiogenic cytokines VEGF (rVEGF), angiopoietin-1 (rAng-1),
angiopoietin-2 (rAng-2) as well as of PlGF (rPlGF) at 4 days after
the gene transfer. hPlGF transcripts were detectable at day 4 in the
peri-infarct borders (Figure 1A). The expression of rPlGF and
rVEGF in the infarct and peri-infarct borders was upregulated to
higher levels in the pPlGF1 group than in the controls (P,0.05)
(Figure 1A, B). Compared to the control groups, pPlGF1 gene
transfer also augmented transcript levels of rAng-1 in the peri-
infarct and remote areas, and of rAng-2 in all areas (P,0.05)
(Figure 1C, D). Thus, pPlGF1 gene transfer transiently elevates
the levels not only of hPlGF1, rPlGF, and rVEGF but also of
rAng-1 and rAng-2.
pPlGF1 transfer enhances vascularization and reduces
infarct size
We then examined whether PlGF1 gene transfer stimulates
revascularization of the ischemic myocardium. To this end, PBS,
500 mg empty vector (Mock) or pPlGF1 was injected intramyo-
cardially in Sprague Dawley rats 20 minutes after ligation of the
LAD. At 28 days after gene transfer, we performed a coronary
microangiography on ex vivo beating hearts, using a third
generation synchrotron radiation microangiography (SRM) [16]
to visualize coronary vessels as small as 20 mm in diameter. This
analysis revealed that pPlGF1 gene transfer stimulated collateral
vessel growth, as more conduit vessels extended into the perfusion
territory of the occluded LAD in the pPlGF1 group than the
controls (Figure 2A). In addition, when counting the density of
isolectin B4 stained microvessels, we found that pPlGF1 gene
transfer stimulated capillary angiogenesis in the ischemic myocar-
dium (P,0.01 for pPlGF1 vs Mock or PBS) (Figure 2B,D).
Since the infarcted myocardium is well known to develop into a
collagen-rich fibrotic scar, we measured the size of the fibrotic area
in the LV as an indirect measure of the infarct size. Masson-
trichrome staining at 28 days after infarction revealed that the
fibrotic area was ,30% smaller in the pPlGF1 group than the
control groups (P,0.01 for pPlGF1 vs Mock and PBS)
(Figure 2C, E). Since the standardized LAD ligation procedure
resulted in a similar ischemic myocardial area at risk in each
group, the finding that pPlGF1 gene transfer reduced the infarct
size indicates that more CMCs survived the ischemic insult in this
group. Indeed, cardiomyocyte apoptosis was significantly more
inhibited in the pPlGF1 group than in the controls (P,0.05 for
pPlGF1 vs Mock and PBS) (Figure 3).
pPlGF1 improves left ventricular function after acute MI
To determine whether pPlGF1 gene transfer improved cardiac
performance, we performed echocardiography at day 5 and 28
after gene transfer. There were no significant differences in
preoperative echocardiographic parameters, LVEDD, LVESD,
FS and RWMS among the pPlGF1, Mock and PBS groups (not
shown). Cardiac performance is known to deteriorate at later
stages after MI and is, in fact, becoming an increasingly more
frequent cause of cardiac failure in post-MI survivors. Echocar-
diography revealed comparable functional parameters in all
groups at day 5 after gene transfer, but an improvement in
cardiac performance selectively in the pPlGF1 group at later times.
Indeed, when determining the change in FS between day 5 and
28, the FS was increased after pPlGF1 but reduced in the control
groups (Figure 2F,G). Similarly, myocardial wall dyskinesis was
reduced in the pPlGF1 group but increased in the controls
(P,0.01 for pPlGF1 vs Mock and PBS) (Figure 2F,G).
pPlGF1 gene transfer reduces cardiomyocyte apoptosis
in vivo
The reduced infarct size after pPlGF1 gene transfer might be
attributable, at least in part, to the possibility that fewer CMCs
died immediately after LAD ligation. As apoptosis is generally
regarded as one of the main mechanisms responsible for ongoing
myocardial degeneration after acute MI, we analyzed the effect of
pPlGF1 transfer on CMC apoptosis by double staining for TdT-
mediated dUTP nick end-labeling (TUNEL) and cardiac tropo-
nin-I (cTn-I) at 4 days after gene transfer. This analysis revealed
that pPlGF1 gene transfer reduced the number of TUNEL
+
CMCs in the infarcted myocardium (% apoptotic CMCs: pPlGF1,
5.961.0%; Mock, 12.162.2%; PBS, 11.561.7%, P,0.01 for
pPlGF1 vs Mock and PBS) (Figure 3A, B).
We next sought to determine the molecular mechanism by
which pPlGF1 transfer reduced CMC apoptosis. As insulin-like
growth factor 1 (IGF-1) and its receptor (IGFR) are well known for
their anti-apoptotic effects on CMCs, we measured endogenous
transcript levels of rat IGF-1 (rIGF-1) and rat IGFR (rIGFR), by
real-time RT-PCR, 4 days after pPlGF1 transfer. Expression of
rIGF-1 and rIGFR was higher in the infarcted and peri-infarct
areas in the pPlGF1 group than control groups (P,0.05)
(Figure 3C). Since survival signals such as IGF-1 activate Akt
via phosphorylation by phosphatidylinositol 3-kinase (PI3-kinase)
and 3-phosphoinositide-dependent kinase (PDK), we determined
the levels of phospho-Akt in the ischemic myocardium at day 4 in
each group. Immunoblotting revealed that phospho-Akt levels
were elevated significantly more in the pPlGF1 group than in the
control groups (Figure 3D). Because phosphorylation of p42/p44
MAPK is also well known to be cardioprotective by promoting cell
survival, we examined the levels of phospho-p42/p44 in the
ischemic myocardium at day 4 in each group. Immunoblotting
revealed that phospho-p42/p44 levels were significantly higher in
the pPlGF1 group than in the controls (Figure 3D). To confirm
that pPlGF1 gene transfer induced survival pathways, we also
analyzed the expression of Bcl-xL, one of the Bcl-2 family of
proteins known to inhibit CMC apoptosis and to be upregulated
by growth factors. Western blotting revealed that Bcl-xL was
overexpressed in the ischemic myocardium at day 4 in the pPlGF1
group as compared to the control groups (Figure 3E). Thus, the
induction, by pPlGF1 gene transfer, of a survival signaling
cascade, involving IGF-1, PI3K-Akt and the anti-apoptotic protein
Bcl-xL, likely contributed to the improved survival of ischemic
CMCs after LAD ligation.
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indirectly via SDF-1
We then assessed whether pPlGF1 gene transfer in bone
marrow transplantation/myocardial infarction/gene therapy
(BMT/MI/GTx) animals mobilized BM-SL cells from the BM
to the infarcted myocardium. FACS analysis at day 7 post-MI
revealed a larger number of circulating GSL cells in the peripheral
blood (PB) of BMT/MI/GTx animals in the pPlGF1 group than
in the control groups (Figure 3A). pPlGF1 gene transfer in BMT/
MI/GTx animals also mobilized more EPCs from the BM. To
identify these BM-derived EPCs in the PB of BMT/MI/GTx
animals, real time RT-PCR was performed using mouse-specific
primers for EPC markers. Expression of mouse Flt-1 (mFlt-1),
mouse Flk-1 (mFlk-1) and mouse CXCR4 (mCXCR4) in SL cells
of PB were significantly greater in the pPlGF1 group than in the
controls at day7 (Figure S1A, B, C). Furthermore, double
immunostaining for GFP and Sca-1 at day 7 after gene transfer
revealed that pPlGF1 gene transfer resulted in recruiting two- to
three-times the number of GFP
+Sca-1
+ cells into the peri-infarct
borders (Figure 4B,C). To further confirm that PlGF was capable
of chemoattracting PB-SL cells, we used a modified Boyden
chamber assay. This analysis revealed that PlGF chemo-attracted
circulating SL cells in a dose-dependent manner (Figure 4D),
with a comparable potency to that of VEGF or SDF-1 (not
shown).
Even though the above findings indicate that hPlGF1 itself is
capable of inducing the proliferation of BM-SL cells in the BM -
mobilizing them from the BM into the PB and recruiting them to
the infarcted myocardium through direct effects on these cells - we
also considered whether hPlGF1 might indirectly stimulate BM-
SL accumulation in the infarct. Since SDF-1 is a chemokine for
CXCR4
+ BM-derived progenitors and known to enhance the
recruitment of BM-derived EPCs into ischemic tissue as well as to
entrap angio-competent CXCR4
+ myeloid cells in peripheral
Figure 1. pPlGF1 upregulates angiogenic factors in ischemic myocardium. A: Real-time PCR revealed that gene expression of hPlGF was
detectable in fibrosis and peri-infarct areas 4 days post pPlGF1 gene transfer. B,C, Real-time PCR revealed that gene expression of rPlGF and rVEGF in
fibrosis and peri-infarct areas was significantly enhanced in the pPlGF1 group compared with controls. D,E, Real-time PCR revealed that expression of
rAng-1 in peri-infarct and remote areas and that of rAng-2 in all areas significantly augmented in the pPlGF1 group compared with controls. *, P,0.05
vs PBS; {,P ,0.05 vs Mock. (n=8 in each group).
doi:10.1371/journal.pone.0024872.g001
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transfer upregulates SDF-1 expression in the ischemic myocardi-
um. Indeed, real-time RT-PCR analysis revealed that rSDF-1
expression levels in the peri-infarct area were elevated more in the
pPlGF1 group than in the controls (Figure 4E). Immunostaining
for SDF-1 at day 7 after gene transfer also revealed that the
number of SDF-1
+ cells was greater in the pPlGF1 group than the
control groups (P,0.01 for pPlGF1 vs Mock and PBS)
(Figure 4F–I). Taken together, pPlGF1 transfer seemed to recruit
BM-derived SL cells into the peri-infarct area either directly or
indirectly through upregulation of the SDF-1/CXCR4 pathway.
pPlGF gene transfer stimulates cardio-myogenesis from
BM-SL cells
We also analyzed the cell fate of the BM-SL cells that were
recruited to the peri-infarct borders by pPlGF1 gene transfer, and
assessed whether they contributed to myocardial or vascular
regeneration. At 7 days after gene transfer in BMT/MI/GTx rats,
cells of the CMC lineage were identified by double immunostain-
ing for GFP and GATA4, or its downstream target gene MEF2C,
which is an established early cardiomyogenic marker. This analysis
revealed that a small fraction of GFP
+ cells in the peri-infarct
borders co-expressed GATA4 or MEF2C in the animals that had
Figure 2. Angiographical or histological evaluation of LV remodeling and myocardial neovascularization after MI. A, Representative
microangiographic images 28 days after PBS, Mock or pPlGF1 injection (7.067.0 mm; scale bar; 100 mm) (arrow: ligation point). B, Representative
histochemical staining for isolectin B4 at day 28 (620). C, Representative Masson-trichrome staining at day 28. D, Capillary density in rats receiving
pPlGF1, Mock or PBS at day 28. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock. E, Ratio of fibrosis area/entire LV area (% fibrosis area) at day 28. **, P,0.01 vs
PBS; {{,P ,0.01 vs Mock. (n=8 in each group). LV functional evaluation by echocardiography. F, Representative recording of M-mode
echocardiography 5 and 28 days after pPlGF1, Mock or PBS injection (arrow, endocardium in lateral wall; arrowhead, endocardium in septal wall). G,
Changes in echocardiographic parameters between day 5 and day 28 after gene transfer (n=8 in all groups). FS, fractional shortening; RWMS,
regional wall motion score. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock. (n=8 in each group).
doi:10.1371/journal.pone.0024872.g002
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marrow-derived CMCs expressing GFP were never or only very
rarely detected in the control groups (Figure 5A, B). These
CMCs appeared morphologically mature and were indistinguish-
able from host CMCs in the peri-infarct and infarct area. Notably,
GATA4
+ and MEF2C
+ cells were also found to express the
Figure 3. pPlGF1 reduces cardiomyocyte (CMC) apoptosis. A: Cardiac apoptosis was detected by the TdT-mediated dUTP nick end-labeling
(TUNEL) assay (green) and cardiac troponin-I (cTn-I) staining. White arrows showed TUNEL-positive CMCs in infarcted myocardium (apoptotic CMCs).
B: Bar graph indicates % apoptotic CMCs, which was calculated as the ratio of the number of TUNEL-positive CMCs to the number of total CMCs in
the infarcted myocardium. The % apoptotic CMCs on day 4 significantly decreased following pPlGF1 injection compared to Mock and PBS
administration. *, P,0.05 vs PBS; {,P ,0.05 vs Mock. C: Real-time PCR demonstrated significant upregulation of endogenous IGF-1 in infarcted and
peri-infarct areas and IGFR at peri-infarct area after pPlGF1 gene transfer compared with the controls. D: Immunoblotting for phospho-Akt and
phospho-p44 or p42 of MAPK revealed enhanced expression of these proteins in the pPlGF1 group than controls. E: Immunoblotting indicated
greater expression of Bcl-xL protein in the pPlGF1 group than in the controls. (n=6 in each group).
doi:10.1371/journal.pone.0024872.g003
Pleiotropic Effects of PlGF on Cardiac Repair
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24872progenitor marker Sca-1 (Figure 5C, D), suggesting that PlGF1
gene transfer induced BM-derived SL progenitor cells to acquire
the characteristics of the CMC lineage. This was further supported
by the finding that certain GFP
+ cells also expressed cTn-I (a
marker of mature CMCs) at 28 days after gene transfer
(Figure 5E,F). Mock and PBS did not switch on CMC marker
expression in GFP
+ BM-SL cells (Figure 5G,H). These findings
suggest that BM-derived cell have the potential to differentiate into
Figure 4. pPlGF1 auguments mobilization of BM progenitors into PB and their recruitment into ischemic myocardium. A,
Representative recording of serial FACS analyses of PB GFP
+/lin
2 cells isolated from xeno-rats in each group. The number of PB GSL cells 7 days after
MI was significantly increased in the pPlGF1 group than controls. *, P,0.05 vs PBS; {,P ,0.05 vs Mock. B, Double immunofluorescent staining for Sca-
1 and GFP (green) in infarcted myocardium of each group at day 7. Arrows show the double positive cells, which indicate BM-derived immature cells
were incorporated into the ischemic area. C, The bar graph showing the number of Sca-1+/GFP+ cells in the ischemic area indicates enhanced
recruitment of the BM-derived immature cells by pPlGF1 gene transfer at day 7. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock. D, Migratory response of PB-
SL cells toward different dosages of PlGF by modified Boyden chamber migration assay. *, P,0.05 vs 0 ng/ml (control). E, Real-time PCR
demonstrated that pPlGF1 significantly augmented expression of rSDF-1 mRNA at the peri-infarct area 4 days after MI compared with controls.
*, P,0.05 vs PBS; {,P ,0.05 vs Mock. F–H, Representative immunofluorescent staining for SDF-1 in PBS (F), Mock (G) or pPLGF1 (H) group 7 days after
gene transfer. Red fluorescence indicates SDF-1 protein in cytoplasms. I, Quantification of SDF-1+ cells at peri-infarcted area in rats receiving pPlGF1,
Mock or PBS at day7. SDF-1+ cells were significantly increased following pPlGF1 gene transfer. **, P,0.01 vs PBS; *, P,0.05 vs Mock; {{,P ,0.01 vs
Mock. (n=8 in each group).
doi:10.1371/journal.pone.0024872.g004
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um. Frequency of the BM-derived CMCs (GFP+/cTn-I+ cells) to
total BM-derived cells (GFP+ cells) was 11.8% in PlGF groups. In
fact, 11.8% of newly formed CMCs derived from BM cells in PlGF
group were developed through transdifferentiation mechanism
between rat and mouse cells, whereas no transdifferentiation was
observed in other groups.
GFP
+ BM-SL cells in the pPlGF1 group were expressed
connexin-43 with cTn-I and integrated with host myocardium
through connexin-43. These findings demonstrated that PlGF
gene therapy was one of the mechanism of restoring the loss of LV
function (Figure S2A–D).
Supporting information Result
See Results S1 (Figure S5, S6, S7, S8, S9, S10, S11, S12,
S13), which are published as supporting information on the PLos
ONE web site.
Discussion
In this paper, we show that myocardial PlGF gene transfer is a
promising novel therapeutic strategy to revascularize and
regenerate the infarcted myocardium and improve its performance
after MI. Besides enhancing angiogenesis, PlGF induced this
beneficial effect via two novel mechanisms, i.e. stimulation of
cardiomyocyte survival, and induction of cardiac myoangiogenesis
by BM progenitor cells, recruited to the infarct (Figure S3). To
the best of our knowledge, this is the first report to document such
a therapeutic potential and these novel mechanisms of PlGF gene
therapy for ischemic heart disease.
Despite its discovery some 15 years ago now [1], the precise
biological role of PlGF has remained puzzling for more than a
decade. Over the last few years, however, PlGF has been
increasingly recognized as contributing to the angiogenic switch
in numerous disorders [1–5,18]. In addition, transgenic overex-
pression or viral gene delivery of PlGF, or administration of
recombinant PlGF enhance angiogenesis and vessel maturation in
the skin and ischemic limb, thus indicating that PlGF has sufficient
angiogenic potency [2,4,6,7]. In this study, we found that PlGF
and VEGFR1 expression levels were upregulated in the ischemic
myocardium in rats, consistent with previous findings in mice and
humans [2,3,7]. Injection of pPlGF1 in the ischemic myocardium
further elevated PlGF levels for period of at least 7 days in vivo.
Interestingly, this burst of PlGF secondarily amplified its own
expression and induced the expression of several other angiogenic
factors (VEGF, Ang1 and Ang2). PlGF may have induced the
release of such angiogenic signals not only from resident cardiac
cells but, perhaps, also from recruited BM-derived progenitors,
similar to its effect on angiocompetent BM-derived VEGFR-1
+
hemangiocytes, as previously documented [19]. This coordinated
joint expression of paracrine angiogenic factors over a period of 7–
10 days after MI sufficed to stimulate the formation of microvessels
(endogenous angiogenesis) as well as of larger conduit vessels
(endogenous arteriogenesis) for up to at least 28 days after MI.
PlGF gene transfer thus stimulated the formation of durable,
mature vessels, that failed to regress upon cessation of PlGF gene
expression. These findings in the ischemic heart in the rat extend
those previous findings in the skin and ischemic limb in mice that
showed that PlGF promotes not only the formation of naked
endothelial-lined channels but also recruits pericytes and smooth
muscle cells around these nascent neovessels, thereby stabilizing
them into more mature and regression-resistant vessels [3].
Importantly, this neovasculature was functional, as it improved
cardiac performance after PlGF gene therapy.
An intriguing but medically relevant finding was that the infarct
size was substantially reduced by myocardial PlGF gene therapy.
Since the standardized procedure of LAD ligation results in a
comparable at-risk ischemic myocardial area, and severely
ischemic cardiomyocytes die within 24 to 48 hours (i.e. before
new vessels are formed and are able to supply oxygen again), these
findings suggest that PlGF gene transfer preserved cardiomyocyte
viability initially via angiogenesis-independent mechanisms. In
fact, echocardiography on day 5 revealed that LV functional
parameters tended to be slightly better preserved in PlGF group
Figure 5. Representative double immunofluorescent staining
for immature cardiomyogenic or vasculogenic markers and
GFP or Sca-1 at day 7. A,B, Double immunofluorescent staining for
GFP and GATA4 (A) or MEF2C (B) at day 7. BM-derived immature CMCs
were identified as cells positive for cytoplasmic GFP (green) and nuclear
GATA4 (A) or MEF2C (B) following pPlGF1 transfer. White arrows show
nuclei of immature BM-derived CMCs (A and B). C,D, Double
immunofluorescent staining for Sca-1 and GATA4 (C) or MEF2C (D)a t
day 7. BM-derived immature CMCs were identified as cells positive for
Sca-1 and nuclear GATA4 (green) (C) or MEF2C (green) (D) following
pPlGF1 transfer. White arrows show nuclei of immature BM-derived
CMCs (C and D). (n=6 in each group). Histological evaluation of
development of BM-derived stem/progenitor cells into CMCs
in rat ischemic myocardium at day 28. E,F: Representative double
immunofluorescent staining for cTn-I and GFP at day 28. BM-derived
CMCs were identified as double positive cells for cTn-I (green) and GFP.
E, merge in pPlGF1 group, 610; F, merge in pPlGF1 group, 640. White
arrows show nuclei of BM-derived CMCs. G,H: Representative double
immunofluorescent staining for cardiac troponin-I (cTn-I) and GFP in
Mock and PBS groups at day 28. BM-derived CMCs were identified as
double positive cells for cTn-I (green) and GFP (red). G, merge in Mock
group, 640; H, merge in PBS group, 640. (n=6 in each group).
doi:10.1371/journal.pone.0024872.g005
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significant (FS: PlGF group, 21.661.6; Empty group, 19.161.6;
PBS group, 20.162.0%; P=0.053) (RWMS: PlGF group,
25.761.3; Empty group, 27.161.1; PBS group, 26.160.7%;
P=0.058). We cannot exclude the possibility that PlGF gene
transfer rescued some of these ischemic myocytes in the peri-
infarct border regions through vasodilation of residual vessels, but
PlGF is a less potent vasodilator than VEGF (data not shown) [20].
Instead, PlGF gene transfer significantly reduced cardiomyocyte
apoptosis, presumably through various complementary mecha-
nisms. PlGF is a survival signal for endothelial cells and
macrophages [9], but a similar activity of repairing endangered
cardiomyocytes has not as yet been demonstrated. An intriguing
question, however, is whether PlGF stimulates cardiomyocyte
survival directly or indirectly. Though VEGFR1 is expressed on
cardiomyocytes ([21] and unpublished observations), PlGF also
stimulates the paracrine release of IGF-1 by cardiac fibroblasts,
which express VEGFR-1 [3,22,23]. IGF-1 is well known for its
effect on myocardial tissue, including stimulation of cardiac
contractility, antiapoptotic effects and improved remodeling after
MI by switching on a cascade of downstream pathways including
activation of pAkt, MAPK and Bcl-xL [24,25]. Moreover, PlGF
also upregulated the expression of VEGF and Ang-1 [26], which
have similar cardioprotective activity [16]. Furthermore, PlGF
gene transfer augmented the accumulation of BM progenitors and
endothelial cells, which release cardioprotective signals [27,28].
The improved cardiac repair, and resultant smaller infarct size,
likely contributed to the augmented cardiac performance after
PlGF gene therapy.
Previous studies reported that VEGF is capable of recruiting
angiocompetent VEGFR-1
+ progenitors from the BM to sites of
tissue regeneration or malignant growth [11,19]. Though PlGF is
known to stimulate cycling and differentiation of VEGFR-1
+ Sca-
1
+lin
2 (SL) cells after myeloablation [29] and to recruit BM-
derived endothelial progenitors to tumors [10], the effects of PlGF
on marrow progenitors have generally been much less character-
ized – especially in conditions of myocardial ischemia. We
observed that PlGF has pleiotropic effects on BM-derived SL
progenitors: (i) in vitro, PlGF dose-dependently stimulated the
proliferation of SL progenitors, harvested from the BM, and was
also capable of chemo-attracting SL cells, that were mobilized in
the PB; (ii) in vivo, myocardial PlGF gene transfer increased the
fraction of GFP
+Sca-1
+lin
2 (GSL) cells in the BM and recruited
these progenitors to the PB and, subsequently, in the peri-infarct
borders in the heart. Apart from serving as a recruitment signal
itself, PlGF also indirectly recruited BM progenitors to the
ischemic heart. Indeed, similar to VEGF [19], PlGF upregulated
myocardial expression of SDF-1, a well known chemo-attractant
and retention signal of angiocompetent BM progenitors [19,21].
Thus, myocardial PlGF gene therapy recruited marrow progen-
itors to the ischemic myocardium both via direct and indirect
paracrine effects.
Consistent with previous findings [30], BM-derived GFP
+
CMCs were only rarely detected in the peri-infarct borders in
control animals after acute MI, suggesting that cardiomyogenesis
is indeed a rare event. An appealing finding, therefore, is that
intramyocardial PlGF gene transfer switched on the expression of
CMC markers – initially of early (GATA-4, MEF-2C) and
subsequently of mature (c-TnI) CMC markers – in at least a
fraction of recruited progenitors. This is remarkable, as only a
limited number of genes are thus far known to induce
cardiomyogenesis of endogenous BM progenitors [31]. Indeed,
many more studies have reported that BM-derived cells, upon
intramyocardial implantation in infarcted hearts, can acquire
functional and structural CMC characteristics without, however,
identifying the responsible cardiomyogenic signals. Although
VEGF promotes cardiomyogenic differentiation of embryonic
stem cells through activation of Flk-1 and Flt-1 [8], the role of
VEGF and PlGF in postnatal cardiomyogenesis has not been fully
investigated. In vitro culture of BM Sca-1+/Lin- cells, with or
without VEGF and PlGF, revealed that the combination of a
higher concentration of PlGF and VEGF, but neither protein
alone, is essential for early cardiac gene expression in BM stem
cells (Figure S4). These results suggest that only PlGF protein
may not directly induce cardiomyogenic differentiation of the BM
stem cells. Certain combined signals from ischemic myocardium
evoked by PlGF gene therapy may be necessary for inducing
cardiomyogenesis in vivo. The fact that the expression of several
angiogenic factors, including VEGF, was augmented following
PlGF gene therapy in vivo may also support this hypothesis. The
relative importance of exogenous cardiomyogenesis versus alter-
native mechanisms (i.e. regeneration by cardiac progenitors or
endogenous CMCs) or cardioprotection (i.e. inhibition of apop-
tosis of endangered CMCs) needs to be defined in the future.
In conclusion, myocardial PlGF gene transfer improves cardiac
performance after acute MI via complementary multi-tasking,
namely, stimulation of endogenous angiogenesis and arteriogenesis
(through direct and indirect paracrine effects), promotion of
exogenous vasculogenesis (through direct and SDF-1-mediated
recruitment of BM-progenitors and induction of endothelial
commitment), cardioprotection (through inhibition of CMC
apoptosis) and regeneration (through cardiomyogenesis).
Supporting Information
Figure S1 A, B, C: Real-time PCR using PB-Sca-1
+/lin
2 (SL)
cells isolated from BMT/MI/GTx rats in each group. pPlGF1
gene transfer significantly enhanced expression of mFlt-1,
mCXCR4 and mFlk-1 mRNA in PB-SL cells 7 days after MI
compared with controls. **, P,0.01 vs PBS; *, P,0.05 vs PBS; {{,
P,0.01 vs Mock; {,P ,0.05 vs Mock. (n=8 in each group).
(TIF)
Figure S2 A-D: Representative immunofluorescent staining for
cardiac troponin-I (cTn-I), GFP and connexin-43 in Mock, PBS
and PlGF groups at day 28. BM-derived cardiomyogenic cells
integrating with host cardiomyocytes were identified as triple
positive cells for connexin-43 (red), cTn-I (blue) and GFP (green).
A, merge in PBS group, 620; B, merge in Mock group, 620. C,
merge in PlGF group, 620; D, merge in PlGF group, higher
magnification. White arrows show integration of the BM-derived
cells with host cardiomyocytes. (n=5 in each group).
(TIF)
Figure S3 Schema of therapeutic mechanisms of local gene
transfer of PlGF for cardiac myoangiogenesis.
(TIF)
Figure S4 PlGF combined with VEGF stimulates the
expression of dexamethasone-induced myoangiogenic
genes in BM stem cells in culture. Real-time PCR for
GATA4 (A), cTnI (B), Flt-1 (C), eNOS (D) and VE-cadherin (E)i n
BM Sca-1+/Lin2 cells in culture. Left panels, mRNA expressions
in BM Sca-1+/Lin2 cells cultured with PlGF (0, 1, 10 or 100 ng/
ml); Right panels, mRNA expressions in BM Sca-1+/Lin2 cells
cultured with VEGF (1 ng/ml) and PlGF (0, 1, 10 or 100 ng/ml).
*, P,0.05 vs PlGF 0; {,P ,0.05 vs PlGF 1. (n=8 in each group).
(TIF)
Figure S5 A: Immunoblotting for hPlGF protein in cell lysate
and culture medium of rat cardiomyoblasts (H9C2) 48 hours after
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only. H9C2 without any transfection was used as negative control
and recombinant hPlGF was prepared as positive control. hPlGF
protein expression was detected in both cell lysate and medium
following PlGF1-IRESeGFP transfer but not after control plasmid
transfection. PlGF signaling pathway is activated following
MI. B: Immunostaining for GFP using infarcted heart samples 4
days after pcDNA3-PlGF1–IRESeGFP plasmid or PBS injection
(610). C: Gene expression of hPlGF in MI tissue was detected at
days 3 and 7 but not at day 14. lane 1, human heart (positive
control); lane 2, PBS at day 3; lane 3, Mock at day 3; lane 4,
phPlGF1 at day 3: lane 5, PBS at day 7; lane 6, Mock at day 7;
lane 7, phPlGF1 at day 7: lane 8, PBS at day 14; lane 9, Mock at
day 14; lane 10, phPlGF1 at day 14. (n=5 in each group). D, E:
ELISA revealed that hPlGF (D) and rVEGF (E) protein were
detectable in plasma of PB 4 days post pPlGF1 gene transfer, but
not in control groups. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock.
(n=5 in each group). F, G: PlGF signaling pathway is activated
following myocardial infarction (MI). Expression of rPlGF (F) and
its receptor rFlt-1 (G) mRNA 4 days after myocardial ischemia are
upregulated. **, P,0.01. (n=5 in each group).
(TIF)
Figure S6 Representative double immunofluorescent
staining for immature cardiomyogenic or vasculogenic
markers and GFP or Sca-1 at day 7. A, B: Double
immunofluorescent staining for GFP and GATA6 (A) or Ets-1
(B) at day 7. BM-derived immature SMCs were detected as cells
positive for cyoplasmic GFP and nuclear GATA6 (A) and the
immature ECs were positive for GFP and Ets-1 (B). White arrows
show nuclei of BM-derived immature SMCs (A) or ECs (B). C, D:
Double immunofluorescent staining for Sca-1 and GATA6 (C)o r
Ets-1 (D) at day 7. BM-derived immature SMCs were detected as
cells positive for Sca-1 and nuclear GATA6 (C) and the immature
ECs were positive for Sca-1 and Ets-1 (D). White arrows show
nuclei of BM-derived immature SMCs (C) or ECs (D). (n=6 in
each group).
(TIF)
Figure S7 Histological evaluation of development of
BM-derived stem/progenitor cells into SMCs or ECs in
rat ischemic myocardium at day 28. A,B: Representative
double immunofluorescent staining for smooth muscle actin
(SMA) and GFP at day 28. BM-derived SMCs were identified as
double positive cells for SMA and GFP (green). A, merge in
pPlGF1 group, 610; B, merge in pPlGF1 group, 640. White
arrows show nuclei of BM-derived SMCs. C, D: Representative
double immunofluorescent staining for smooth muscle actin
(SMA) and GFP in Mock and PBS groups at day 28. BM-derived
SMCs were identified as double positive cells for SMA (red) and
GFP (green). C, merge in Mock group, 640; D, merge in PBS
group, 640. E, F: Representative double immunofluorescent
staining for isolectin B4 (ILB4) (green) and GFP at day 28. BM-
derived ECs were identified as double positive cells for ILB4 and
GFP. E, merge in pPlGF1 group,610; F, merge in pPlGF1 group,
640. White arrows show nuclei of BM-derived ECs. G, H:
Representative double immunofluorescent staining for isolectin B4
(ILB4) (green) and GFP (red) in Mock and PBS groups at day 28.
G, merge in Mock group, 640; H, merge in PBS group, 640.
(n=6 in each group).
(TIF)
Figure S8 LV functional evaluation by echocardiography and a
micro-tip conductance catheter. Invasive hemodynamic parame-
ters 28 days after pPlGF1, Mock or PBS injection. +dP/dt and
2dP/dt, maximum and minimum derivative of LV pressure. ** or
{{,P ,0.01 vs PBS or Mock; {,P ,0.05 vs Mock. (n=8 in each
group).
(TIF)
Figure S9 pPlGF1 upregulates proliferation and surviv-
al of the BM progenitors. A: BrdU incorporation revealed
dose-dependent increase in proliferative activity of BM-SL cells
after adding PlGF protein. *, P,0.05 vs 0 ng/ml; **, P,0.01 vs
0 ng/ml. B: The number of BM-SL cells in each well 1 week after
cultivation increased by adding PlGF in a dose-dependent manner.
*,P,0.05 vs0 ng/ml;**,P,0.01vs0 ng/ml.(n=6 ineachgroup).
(TIF)
Figure S10 pPlGF1 upregulates proliferation and sur-
vival of the BM progenitors. A: The number of BM total
MNCs obtained from xeno-rats was greater in the pPlGF1 group
than controls. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock. B:
Representative examples of serial FACS analysis of BM-GFP
+/
lin
2 cells of xeno-rats in each group. Yellow colored population
indicated GFP+/Sca-1+/lineage- (GSL) cells in BM of xeno-rats.
**, P,0.01 vs PBS; {{,P ,0.01 vs Mock. C: Percent of GSL cells
in BM 7 and 28 days after MI was significantly increased in the
pPlGF1 group than controls. **, P,0.01 vs PBS; {{,P ,0.01 vs
Mock. D: Immunoblotting for Akt, phospho-Akt and phospho-
p44 or p42 MAPK in BM-SL cells 7 days after MI. Expression of
these proteins was upregulated more in the pPlGF1 group than
controls. (n=6 in each group).
(TIF)
Figure S11 pPlGF1 enhances cell growth-related signals
in ischemic myocardium (endothelial cells). A: Double
immunofluorecent staining for phospho-Akt (pAkt, green) and
isolectin B4 (ILB4, red). Double positive cells (white arrows) were
identified as growing endothelial cells 7 days after administration
of pPlGF1, Mock or PBS. B: Quantification of pAkt+/ILB4+ cells
at peri-infarcted area in rats receiving pPlGF1, Mock or PBS at
day 7. **, P,0.01 vs PBS; {{,P ,0.01 vs Mock. C: Double
Immunofluorecent staining for activated-MAPK (green) and IlB4
(red) at day 7. Double positive cells (white arrows) were identified
as growing endothelial cells. D: Quantification of activated-
MAPK+/ILB4+ cells at peri-infarcted area in rats receiving
pPlGF1, Mock or PBS at day 7. **, P,0.01 vs PBS; {{,P ,0.01 vs
Mock. (n=6 in each group).
(TIF)
Figure S12 pPlGF1 enhances cell growth-related signals
in ischemic myocardium (cardiomyocytes). A: Double
staining for activated-MAPK (green) and cardiac troponin I (cTnI,
red) at day 7. Double positive cells (white arrowheads) were
identified as growing cardiomyocytes. B: Quantification of
activated-MAPK+/cTnI+ cells at peri-infarcted area in rats
receiving pPlGF1, Mock or PBS at day 7. (n=6 in each group).
(TIF)
Figure S13 A: Representative morphology of small and large
endothelial progenitor cell (EPC) colonies. B: In EPC colony
forming assay in BM-SL cells of xeno-rats, the number of small
EPC colonies, large EPC colonies and total EPC colonies were
significantly greater in the pPlGF1 group than controls. *, P,0.05
vs PBS; {,P ,0.05 vs Mock. (n=6 in each group).
(TIF)
Results S1 Supporting Information Results.
(DOC)
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